Ticker Details
Biogen Inc. Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$30.84B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$2.66 | 1.46%
Avg Daily Range (30 D):	$4.66 | 2.32%
Avg Daily Range (90 D):	$3.68 | 1.91%

Institutional Daily Volume
Avg Daily Volume:	2.03M
Avg Daily Volume (30 D):	.99M
Avg Daily Volume (90 D):	.9M

Trade Size
Avg Trade Size (Sh.):	104
Avg Trade Size (Sh.) (30 D):	40
Avg Trade Size (Sh.) (90 D):	39

Institutional Trades
Total Institutional Trades:	45,082
Avg Institutional Trade:	$6.26M
Avg Institutional Trade (30 D):	$18.6M
Avg Institutional Trade (90 D):	$16.88M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	7

Market Closing Trades
Avg Closing Trade:	$28.79M
Avg Closing Trade (30 D):	$63.67M
Avg Closing Trade (90 D):	$49.04M
Avg Closing Volume:	140.84K

News

Jul 15, 2026 @ 3:00 PM Autoimmune Disease Therapeutics Market Size to Rea... Source: Sns Insider

Jul 6, 2026 @ 11:00 AM Grey Matters Takes Delivery of the First Brain Ded... Source: Grey Matters Health Inc.

Jul 4, 2026 @ 8:02 AM Biogen Is Paying $1 Billion for a Company That Won... Source: Adria Cimino

Jun 29, 2026 @ 12:00 PM Block & Leviton LLP Announces Proposed Class Actio... Source: Block & Leviton Llp

Jun 23, 2026 @ 9:58 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$9.35	$2.17	$-.33
Diluted EPS	$9.3	$2.15	$-.35
Revenue	$9.94B	$2.48B	$2.28B
Gross Profit	$7.5B	$1.82B	$1.78B
Net Income / Loss	$1.37B	$319.5M	$-48.9M
Operating Income / Loss	$1.62B	$377.7M	$-56M
Cost of Revenue	$2.44B	$661M	$495.5M
Net Cash Flow	$784.4M	$374.2M	$-854.3M
PE Ratio

Splits
Jan 18, 2001	3:1